|

Risk-guided Disease managEment Plan to prevEnt CAD in Patients Treated With Previous Cancer

RECRUITINGSponsored by Baker Heart and Diabetes Institute
Actively Recruiting
SponsorBaker Heart and Diabetes Institute
Started2023-10-18
Est. completion2026-05
Eligibility
Age40 Years – 70 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05366153

Summary

REDEEM-CAD is a prospective multi-centre study of CAD risk evaluation and management in cancer survivors 40-70 years with chemotherapy or radiotherapy \>5 years ago.

Eligibility

Age: 40 Years – 70 YearsHealthy volunteers accepted
Inclusion Criteria:

A history of cancer \>5 y ago associated with potential cardiotoxicity from chemotherapy and/or radiotherapy (chiefly survivors of breast cancer, Hodgkin's lymphoma and prostate cancer).

Exclusion Criteria:

* Unable to provide written informed consent to participate in this study
* Known coronary artery disease at recruitment
* History of previous coronary artery disease
* Inability to acquire interpretable CT images
* Contraindications/Intolerance to or already taking statin therapy
* Oncologic (or other) life expectancy \<12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial

Conditions3

CancerCoronary Artery DiseaseHeart Disease

Browse More Trials

Cancer trialsHeart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.